This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
A subvariant of the omicron COVID-19 variant called BA.2 is causing an outbreak overseas. Now, some health experts worry it could also lead to an increase in COVID-19 cases in the U.S. Dr. Amesh Adalja, infectious disease specialist and senior scholar at Johns Hopkins Center for Health Security, joins Cheddar News to discuss.
Dr. Alan Kaplin, Chief Scientific Officer of MyMD, joins Cheddar Innovates to discuss how the MYMD-1 is on track to be the first FDA-approved drug to treat aging and age-related diseases.
Tyler Hayes, CEO of Atom Limbs, joins Cheddar Innovates to discuss how the Atom Touch prosthetic is different from other prosthetics on the market, and how the Atom Limbs team of former Apple and Tesla leaders are bringing innovation into this industry.
Nouveau Monde Graphite says it wants to power the sustainable energy revolution. The Canadian company is developing carbon-neutral battery materials to serve the growing EV and cleantech markets and is doing so via a mining and manufacturing operation in Quebec. Eric Desaulniers, founder, president & CEO of Nouveau Monde Graphite, joins Cheddar News' Closing Bell to discuss.
Health experts are warning an even more contagious subvariant of Omicron, known as BA.2, could soon lead to another surge in Covid cases here in the U.S. The variant has already driven cases to skyrocket in China and Europe, which has historically served as a preview to the pattern the U.S. has seen throughout the pandemic. This comes at a time when protection from booster shots is waning for most people who got them. Dr. Jen Caudle, Family Physician & Associate Professor at Rowan University, explains what we can do to protect ourselves against the new variant and how we should act as warnings of another surge rise.
Catching you up on what you need to know Mar 24, 2022, with NATO meeting updates, Ukraine retaking suburbs around Kyiv, the spread of omicron subvariant BA.2 in China, Google Pay launching a third-party billing option, and a 16-year-old is suspected of being the Lapsus$ mastermind behind hacks of Microsoft and others.
Cannabis producer Cresco Labs is acquiring rival Columbia Care in a $2 billion all-stock deal, creating the largest U.S. cannabis company by sales. The deal, which is expected to close in the fourth quarter of 2022, is one of the biggest in the industry's history and would make Cresco the dominant player in a market projected to reach $46 billion in revenue by 2026. Charlie Bachtell, CEO of Cresco Labs, joins Cheddar News' Closing Bell to discuss.
Moderna announced it's seeking emergency use approval for its COVID-19 vaccine from the FDA for children under 6 years old. A former FDA associate commissioner and the president and co-founder of the Center for Medicine in the Public Interest (CMPI) Peter Pitts joined Cheddar News to talk about the timeline, benefits, and risks that come with the approval of the vaccine. "We want to protect their parents and their grandparents and their caregivers and their daycare providers, so it's all about protecting not just the kids but all around the people that are surrounding those kids," he said.
Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers. The company announced early findings Wednesday from a study of children younger than 6.
Catching you up on what you Need to Know on Mar 23, 2022, as NATO meets in Brussels to discuss Ukraine, mortgage rates rise, Justin Trudeau is set to lead Canada until 2025, tornadoes sweep through Louisiana, California may do away with SATs, and a Starbucks in Seattle unionizes.
